Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell
Boston Scientific shares fell nearly 18% in after-hours trading Wednesday after the company reported disappointing electrophysiology sales and lowered its 2026 growth outlook. U.S. demand for the Watchman implant also missed expectations. The company guided first-quarter adjusted EPS to $0.78–$0.80 and organic revenue growth of 8.5%–10%. Analysts are watching for further estimate cuts and commentary on heart-rhythm procedure trends.